Consensus Altimmune, Inc.

Equities

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-06-16 EDT			5-day change	1st Jan Change
6.870 ^USD	-0.72%		+22.24%	-4.72%

05-23	Altimmune, Inc., Q1 2025 Earnings Call, May 13, 2025
05-19	Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder	RE

Evolution of the Average Target: Altimmune, Inc.

Evolution of the Target Price: Altimmune, Inc.

Changes in Analyst Recommendations: Altimmune, Inc.

08b414089788fb7f66897770f9.2S15YyBQ3jIczzAEmnwPO1gIe5KlrXuO1e-9p-dmC4o.6EhNG3lokVRdvGRh6gZeVB5mS_6WgBq3stvt44kFaeaoXww2Tj2tSlC7Uw~9049f6dd3356158f4a6dfb543ac1ceda

Analysts' recommendations: Altimmune, Inc.

William Blair Initiates Altimmune at Market Perform	02-28	MT
Stifel Initiates Altimmune at Buy With $18 Price Target	01-08	MT
UBS Initiates Altimmune at Buy With $26 Price Target	11-12	MT
Guggenheim Downgrades Altimmune to Neutral From Buy	24-04-29	MT
B. Riley Raises Altimmune's PT to $20 From $15 on Increased Obesity+NASH Therapeutics' Product Sales Projections; Keeps Buy Rating	24-01-17	MT
B. Riley Lowers Altimmune's PT to 8 From $15, Says Updated Model Adjusts for Ongoing Obesity+NASH Market Dynamics; Maintains Buy Rating	23-11-09	MT
HC Wainwright Adjusts Price Target on Altimmune to $15 From $50, Maintains Buy Rating	23-08-14	MT
B. Riley Lowers Altimmune's Price Target to $15 From $20, Keeps Buy Rating	23-08-11	MT
B. Riley Lowers Altimmune's Price Target to $20 From $26, Keeps Buy Rating	23-08-10	MT
Goldman Sachs Downgrades Altimmune to Neutral From Buy, Adjusts Price Target to $6 From $20	23-03-22	MT
HC Wainwright Reiterates Altimmune at Buy With $50 Price Target	23-01-20	MT
Evercore ISI Adjusts Altimmune Price Target to $25 From $14, Maintains Outperform Rating	23-01-18	MT
Goldman Sachs Initiates Altimmune at Buy With $20 Price Target	22-12-01	MT
JMP Securities Adjusts Price Target on Altimmune to $26 From $28, Maintains Market Outperform Rating	22-11-11	MT
Guggenheim Adjusts Altimmune's Price Target to $26 From $31, Reiterates Buy Rating	22-09-16	MT
Jefferies Adjusts Altimmune's Price Target to $35 From $30, Reiterates Buy Rating	22-08-31	MT
HC Wainwright Adjusts Altimmune's Price Target to $50 From $25, Reiterates Buy Rating	22-08-17	MT
B. Riley Securities Raises Altimmune's Price Target to $26 from $21, Increases Likelihood of Technical, Regulatory Success; Keeps Buy Rating	22-08-12	MT
Piper Sandler Adjusts Altimmune's Price Target to $25 From $34, Reiterates Overweight Rating	22-05-18	MT
Guggenheim Adjusts Altimmune's Price Target to $28 From $33, Reiterates Buy Rating	22-03-16	MT
B. Riley Lowers Altimmune's Price Target to $21 from $27 After Revising Cost Capital Assumptions, Keeps Buy Rating	22-01-24	MT
ALTIMMUNE : Piper Sandler Adjusts Altimmune's Price Target to $34 from $16, Keeps Overweight Rating	21-09-08	MT
ALTIMMUNE : B. Riley Raises Altimmune's PT to $27 from $21 Ahead of 12-Week Weight Loss Readout from ALT-801 Study, Keeps Buy Rating	21-09-07	MT
ALTIMMUNE : Jefferies Adjusts Altimmune's Price Target to $30 From $14, Reiterates Buy Rating	21-08-12	MT
ALTIMMUNE : Guggenheim Adjusts Altimmune's Price Target to $42 From $52, Reiterates Buy Rating	21-06-30	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus (Composite)	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Ecart obj. / dr
	ALTIMMUNE, INC.					+199.21%
	REGENERON PHARMACEUTICALS, INC.					+39.13%
	ARGENX SE					+38.76%
	BEONE MEDICINES LTD.					+25.55%
	WUXI APPTEC CO., LTD.					+20.96%
	BIONTECH SE					+27.46%
	INSMED INCORPORATED					+8.34%
	SUMMIT THERAPEUTICS INC.					+74.64%
	WUXI BIOLOGICS (CAYMAN) INC.					+10.31%
	GENMAB A/S					+31.74%
	Average					+47.61%
	Weighted average by Cap.					+31.81%